Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic

International Journal of Cancer

Volumn 108, Issue 1, 2004, Pages 146-151

  Shiozawa, Ken ^a   Okai, Mikio ^a,b   Soda, Hiroshi ^a   Yoshikawa, Megumi ^c   Ikegami, Yoji ^c   Tsurutani, Junji ^a   Nakatomi, Katsumi ^a   Nakamura, Yoichi ^a   Doi, Seiji ^a   Kitazaki, Takeshi ^a   Mizuta, Yohei ^a   Murase, Kunihiko ^a   Yoshida, Hisahiro ^c   Ross, Douglas D ^d   Kohno, Shigeru ^b  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

ATP binding cassette transporter; Breast cancer resistance protein; Camptothecin; Drug resistance; Lung cancer; Multidrug resistance; Reversal drug; Topoisomerase I inhibitor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBIOTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; COUMAMYCIN; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOXANTRONE; NOVOBIOCIN; PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BREAST CARCINOMA; CELL MEMBRANE; CONTROLLED STUDY; DRUG RESISTANCE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KINETICS; MEMBRANE TRANSPORT; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINOCOUMARINS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CAMPTOTHECIN; COUMARINS; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MITOXANTRONE; NEOPLASM PROTEINS; NOVOBIOCIN; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 10744232004     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11528     Document Type: Article

References (24)

1. Borst P, Oude Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
2. Doyle LA, Yang W, Abruzzo LV, Krogman T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
3. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002;1:427-34.
4. Kawabata S, Oka M, Shiozawa K, Nakatomi K, Tsukamoto K, Soda H, Fukuda M, Tsurutani J, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001;280:1216-23.
5. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, Shiozawa K, Kawabata S, Soda H, Tanabe S, Kohno S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun 2001;288:827-32.
6. Gellert M, O'Dea MH, Itoh T, Tomizawa J. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci USA 1976;73:4474-8.
7. DeJong S, Timmer-Bosscha H, DeVries E, Mulder NH. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. Int J Cancer 1993;53:110-7.
8. Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest 1987;79:1524-8.
9. Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE, Frei E. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Cancer Res 1989;49: 595-8.
10. Rappa G, Lorico A, Sartorelli AC. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Cancer Res 1992;52:2782-90.
11. Rappa G, Lorico A, Sartorelli AC. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Cancer Res 1993;53:5487-93.
12. Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF, Sartorelli AC. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res 1995;55:4352-60.
13. Rappa G, Murren JR, Johnson LM, Lorico A, Sartorelli AC. Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells. Anticancer Drug 2000;15127-34.
14. Ellis GK, Crowley J, Livingston RB, Goodwin JW, Hutchins L, Allen A. Cisplatin and novobiocin in the treatment of non-small cell lung cancer: a Southwest Oncology Group study. Cancer 1991;67:2969-73.
15. Eder JP, Wheeler CA, Teicher BA, Schnipper LE. A phase 1 clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res 1991;51:510-3.
16. Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL, Davidson NE. Phase 1 and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 1995;13:1136-43.
17. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992;52:6175-81.
18. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Sci Appl 1997;691:161-71.
19. Murren JR, DiStasio SA, Lorico A. McKeon A, Zuhowski EG, Egorin MJ, Sartorelli AC. Rappa G. Phase 1 and pharmacokinetic study of novobiocin in combination with VP-16 in patients with refractory malignancies. Cancer J 2000;6:256-65.
20. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, Schneider E. Methotrexate cross-resistance in a mitoxantrone-selecte multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21.
21. Yang C-H, Schneider E, Kuo M-L, Volk EL, Rocchi E, Chen Y-C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochemi Pharmacol 2000;60:831-7.
22. Wright WW, Putnam LE, Welch H. Novobiocin serum concentrations and urinary excretion following oral administration in man. Antibiot Med 1956;2:311-6.
23. Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JHM. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-50.
24. Ross DD, Karp JE, Chen TT. Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000;96:365-8.